Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Jan 9, 2026 | Flu Shots, Influenza, News, Preventive Care, Vaccinations, Wellness
Earlier this fall, we shared a reminder about the importance of annual flu vaccination and early-season planning. That guidance still holds – but this year’s flu season has raised the stakes. According to the CDC, flu activity has reached its highest level in...
May 5, 2025 | Legislative, News, Pharmacy, Pharmacy Benefits Manager (PBM), State legislation
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
Mar 24, 2025 | Drug costs, Lawsuits, News, Pharmacy Benefits Manager (PBM), Prescription
Current and former employees are suing the financial services firm JPMorgan for allowing inflated drug prices through its partnership with pharmacy benefits manager (PBM) CVS Caremark. The plaintiffs claim that poor PBM oversight led to unnecessarily high prescription...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
Jan 10, 2025 | Drug costs, Drug reimportation, News
Pharmaceutical companies are planning to increase prices on over 250 brand-name medications in the United States at the beginning of 2025, according to an analysis by health care research firm 3 Axis Advisors. That’s a notable drop from last January, during...
